Novartis acquires Excellergy to bolster allergy portfolio

The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments

AstraZeneca’s breakthrough COPD drug Tozorakimab slashes flare-ups in landmark Phase III trials

High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo

Lonza launches Singapore Media Development Lab to cut biomanufacturing risk

The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes

MGM Healthcare builds world’s largest intestinal transplant program in 3 years

Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone

India gets first real-time GLP-1 therapy monitoring platform

As Tracky launches integrated health solution

Cambrex advances $120M US API expansion with Charles City Engineering milestone

The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026

Zealand Pharma launches major US research hub in Cambridge, Massachusetts

The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities

Semaglutide not a “Quick Fix”: Top docs urge holistic approach as drug goes off patent in India

They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.

Merck strikes $6.7 billion deal to acquire terns, bolstering cancer pipeline

TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances

New diabetes drug UBT251 shows strong phase 2 results in China